DK3472183T3 - Variant adeno-associerede virus og fremgangsmåder til anvendelse - Google Patents
Variant adeno-associerede virus og fremgangsmåder til anvendelse Download PDFInfo
- Publication number
- DK3472183T3 DK3472183T3 DK17734575.8T DK17734575T DK3472183T3 DK 3472183 T3 DK3472183 T3 DK 3472183T3 DK 17734575 T DK17734575 T DK 17734575T DK 3472183 T3 DK3472183 T3 DK 3472183T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- associated viruses
- variant adeno
- adeno
- variant
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6027—Vectors comprising as targeting moiety peptide derived from defined protein from viruses ssDNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662350361P | 2016-06-15 | 2016-06-15 | |
US201662404585P | 2016-10-05 | 2016-10-05 | |
PCT/US2017/037781 WO2017218842A1 (en) | 2016-06-15 | 2017-06-15 | Variant adeno-associated viruses and methods of using |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3472183T3 true DK3472183T3 (da) | 2023-11-06 |
Family
ID=59258370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17734575.8T DK3472183T3 (da) | 2016-06-15 | 2017-06-15 | Variant adeno-associerede virus og fremgangsmåder til anvendelse |
Country Status (27)
Country | Link |
---|---|
US (2) | US10961282B2 (da) |
EP (2) | EP4268852A3 (da) |
JP (2) | JP7094277B2 (da) |
KR (2) | KR20230054754A (da) |
CN (2) | CN116003532A (da) |
AU (2) | AU2017286652B2 (da) |
BR (1) | BR112018076090A2 (da) |
CA (1) | CA3028113A1 (da) |
DK (1) | DK3472183T3 (da) |
EA (1) | EA201990033A1 (da) |
ES (1) | ES2962611T3 (da) |
FI (1) | FI3472183T3 (da) |
HR (1) | HRP20231403T1 (da) |
HU (1) | HUE063755T2 (da) |
IL (2) | IL300981A (da) |
LT (1) | LT3472183T (da) |
MA (1) | MA44546B1 (da) |
MX (2) | MX2018015770A (da) |
MY (1) | MY190221A (da) |
PH (1) | PH12018502664A1 (da) |
PL (1) | PL3472183T3 (da) |
PT (1) | PT3472183T (da) |
RS (1) | RS64769B1 (da) |
SG (1) | SG11201811189RA (da) |
SI (1) | SI3472183T1 (da) |
WO (1) | WO2017218842A1 (da) |
ZA (1) | ZA201900278B (da) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6600624B2 (ja) | 2013-05-31 | 2019-10-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アデノ随伴ウイルス変異体及びその使用方法 |
EP3445773B1 (en) | 2016-05-13 | 2022-12-28 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
BR112019001815A2 (pt) * | 2016-07-29 | 2019-05-07 | The Regents Of The University Of California | vírions do vírus adeno-associado com capsídeo variante e seus métodos de uso |
WO2019046069A1 (en) | 2017-08-28 | 2019-03-07 | The Regents Of The University Of California | ADENO-ASSOCIATED VIRUS CAPSID VARIANTS AND METHODS OF USE |
SG11202003287UA (en) * | 2017-10-16 | 2020-05-28 | Vigeneron Gmbh | Aav vectors |
CN113301956A (zh) * | 2018-07-31 | 2021-08-24 | 康奈尔大学 | 控制器官功能的基因治疗方法 |
WO2020068990A1 (en) | 2018-09-26 | 2020-04-02 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
EP4007609A1 (en) * | 2019-08-01 | 2022-06-08 | Cornell University | Targeted gene therapy to treat neurological diseases |
CN111825772B (zh) * | 2020-07-30 | 2023-10-20 | 中国科学院精密测量科学与技术创新研究院 | 具有变异衣壳蛋白的腺相关病毒及其应用 |
MX2023000968A (es) | 2020-08-06 | 2023-03-01 | Fundacion Para La Investig Medica Aplicada | Particulas virales para usarse en el tratamiento contra tauopatias tales como enfermedad de alzheimer mediante terapia genica. |
EP4263575A1 (en) * | 2020-12-16 | 2023-10-25 | Children's Medical Research Institute | Adeno-associated virus capsids and vectors |
EP4263574A1 (en) * | 2020-12-16 | 2023-10-25 | Children's Medical Research Institute | Aav capsids and vectors |
CA3222723A1 (en) | 2021-06-17 | 2022-12-22 | Florian DZIOPA | Aav manufacturing methods |
KR20240055728A (ko) | 2021-07-14 | 2024-04-29 | 메이라지티엑스 유케이 Ii 리미티드 | Retgc 유전자 요법 |
WO2023285986A1 (en) | 2021-07-14 | 2023-01-19 | Meiragtx Uk Ii Limited | Kcnv2 gene therapy |
WO2023288184A2 (en) * | 2021-07-14 | 2023-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for treating chronic pain and for retrograde transduction of neurons |
CN118434758A (zh) | 2021-12-15 | 2024-08-02 | 梅里特斯英国第二有限公司 | 肠肽的多顺反子表达 |
WO2023192450A1 (en) * | 2022-03-30 | 2023-10-05 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Adeno-associated virus vectors for nucleic acid delivery to retinal ganglion cells and/or retinal pigment epithelium cells |
WO2024059667A2 (en) * | 2022-09-13 | 2024-03-21 | Dyno Therapeutics, Inc. | Capsid variants and methods of using the same |
WO2024056902A2 (en) | 2022-09-16 | 2024-03-21 | Christopher Shaw | Compositions and methods for treating neurological diseases |
WO2024079531A2 (en) | 2022-10-11 | 2024-04-18 | Meiragtx Uk Ii Limited | Nucleic acid regulatory elements for gene expression in the liver and methods of use |
WO2024079657A1 (en) | 2022-10-11 | 2024-04-18 | Meiragtx Uk Ii Limited | Formulations for aav gene therapy |
WO2024079662A1 (en) | 2022-10-11 | 2024-04-18 | Meiragtx Uk Ii Limited | Upf1 expression constructs |
WO2024079661A1 (en) | 2022-10-11 | 2024-04-18 | Meiragtx Uk Ii Limited | Atp7b gene therapy |
WO2024079655A1 (en) | 2022-10-11 | 2024-04-18 | Meiragtx Uk Ii Limited | Chromatography methods for purification of aav capsids |
WO2024126696A1 (en) | 2022-12-14 | 2024-06-20 | King's College London | Compositions and methods for treating neurological diseases |
WO2024161022A2 (en) | 2023-02-03 | 2024-08-08 | King's College London | Compositions and methods for treating neurological diseases |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
US9233131B2 (en) * | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
US20090215870A1 (en) * | 2005-04-29 | 2009-08-27 | Terwilliger Ernest F | Compositions and methods for targeting of viral vectors |
US20090215879A1 (en) | 2008-02-26 | 2009-08-27 | University Of North Carolina At Chapel Hill | Methods and compositions for adeno-associated virus (aav) with hi loop mutations |
ES2634118T3 (es) | 2009-02-11 | 2017-09-26 | The University Of North Carolina At Chapel Hill | Vectores de virus modificados y métodos para fabricar y utilizar los mismos |
DK3693025T3 (da) * | 2011-04-22 | 2022-01-10 | Univ California | Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf |
US9719992B2 (en) | 2011-10-07 | 2017-08-01 | Howard Hughes Medical Institute | Genetically encoded biosensors |
WO2013174760A1 (en) * | 2012-05-25 | 2013-11-28 | Deutsches Krebsforschungszentrum | Optimized aav-vectors for high transduction rates in dendritic cells |
US9518980B2 (en) | 2012-10-10 | 2016-12-13 | Howard Hughes Medical Institute | Genetically encoded calcium indicators |
US9518996B2 (en) | 2013-08-05 | 2016-12-13 | Howard Hughes Medical Institute | Fluorescent protein-based calcium integrators |
WO2015038958A1 (en) * | 2013-09-13 | 2015-03-19 | California Institute Of Technology | Selective recovery |
CN104592364B (zh) * | 2013-10-30 | 2018-05-01 | 北京大学 | 定点突变和定点修饰的腺相关病毒、其制备方法及应用 |
GB201403684D0 (en) * | 2014-03-03 | 2014-04-16 | King S College London | Vector |
US10746742B2 (en) * | 2014-04-25 | 2020-08-18 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
WO2016054554A1 (en) * | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Heterologous targeting peptide grafted aavs |
CN107532173A (zh) * | 2014-11-21 | 2018-01-02 | 北卡罗来纳-查佩尔山大学 | 靶向中枢神经***的aav载体 |
US9644007B2 (en) | 2014-12-23 | 2017-05-09 | Howard Hughes Medical Institute | Red genetically encoded calcium indicators and methods of use |
EP3445773B1 (en) | 2016-05-13 | 2022-12-28 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
BR112019001815A2 (pt) * | 2016-07-29 | 2019-05-07 | The Regents Of The University Of California | vírions do vírus adeno-associado com capsídeo variante e seus métodos de uso |
-
2017
- 2017-06-14 MA MA44546A patent/MA44546B1/fr unknown
- 2017-06-15 LT LTEPPCT/US2017/037781T patent/LT3472183T/lt unknown
- 2017-06-15 HU HUE17734575A patent/HUE063755T2/hu unknown
- 2017-06-15 AU AU2017286652A patent/AU2017286652B2/en active Active
- 2017-06-15 KR KR1020237012530A patent/KR20230054754A/ko not_active Application Discontinuation
- 2017-06-15 FI FIEP17734575.8T patent/FI3472183T3/fi active
- 2017-06-15 EP EP23190144.8A patent/EP4268852A3/en active Pending
- 2017-06-15 CN CN202211294452.6A patent/CN116003532A/zh active Pending
- 2017-06-15 BR BR112018076090-0A patent/BR112018076090A2/pt unknown
- 2017-06-15 MX MX2018015770A patent/MX2018015770A/es unknown
- 2017-06-15 EA EA201990033A patent/EA201990033A1/ru unknown
- 2017-06-15 KR KR1020197001327A patent/KR102522661B1/ko active IP Right Grant
- 2017-06-15 HR HRP20231403TT patent/HRP20231403T1/hr unknown
- 2017-06-15 RS RS20231029A patent/RS64769B1/sr unknown
- 2017-06-15 WO PCT/US2017/037781 patent/WO2017218842A1/en active Application Filing
- 2017-06-15 PT PT177345758T patent/PT3472183T/pt unknown
- 2017-06-15 IL IL300981A patent/IL300981A/en unknown
- 2017-06-15 SI SI201731418T patent/SI3472183T1/sl unknown
- 2017-06-15 ES ES17734575T patent/ES2962611T3/es active Active
- 2017-06-15 SG SG11201811189RA patent/SG11201811189RA/en unknown
- 2017-06-15 US US16/310,332 patent/US10961282B2/en active Active
- 2017-06-15 CA CA3028113A patent/CA3028113A1/en active Pending
- 2017-06-15 JP JP2019518172A patent/JP7094277B2/ja active Active
- 2017-06-15 MY MYPI2018002591A patent/MY190221A/en unknown
- 2017-06-15 IL IL263719A patent/IL263719B2/en unknown
- 2017-06-15 PL PL17734575.8T patent/PL3472183T3/pl unknown
- 2017-06-15 EP EP17734575.8A patent/EP3472183B1/en active Active
- 2017-06-15 DK DK17734575.8T patent/DK3472183T3/da active
- 2017-06-15 CN CN201780044853.7A patent/CN109641939B/zh active Active
-
2018
- 2018-12-14 MX MX2024000505A patent/MX2024000505A/es unknown
- 2018-12-17 PH PH12018502664A patent/PH12018502664A1/en unknown
-
2019
- 2019-01-15 ZA ZA2019/00278A patent/ZA201900278B/en unknown
-
2021
- 2021-03-23 US US17/209,336 patent/US11939355B2/en active Active
- 2021-09-03 AU AU2021225247A patent/AU2021225247B2/en active Active
-
2022
- 2022-06-21 JP JP2022099286A patent/JP2022126759A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3472183T3 (da) | Variant adeno-associerede virus og fremgangsmåder til anvendelse | |
DK3684423T3 (da) | Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf | |
DK3445773T3 (da) | Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf | |
HK1246355A1 (zh) | 腺相關病毒變體及其使用方法 | |
DK3445388T3 (da) | Materialer og fremgangsmåder til behandling af hæmoglobinopatier | |
DK3400291T3 (da) | Manipuleret virus | |
DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
DK3653221T3 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
DK3390430T3 (da) | Human immundefektvirus-antigener, vektorer, sammensætninger og fremgangsmåder til anvendelse deraf | |
DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
DK3259597T3 (da) | Pvrig-polypeptider og fremgangsmåder til behandling | |
DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
DK3160470T3 (da) | Analoger af pridopidin, fremstilling og anvendelse heraf | |
BR112016016289A2 (pt) | heteroaris e usos dos mesmos | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3227675T3 (da) | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom | |
DK3198009T3 (da) | Onkolytiske tumorvira og anvendelsesfremgangsmåder | |
DK3551209T3 (da) | Insulin-fc-fusioner og fremgangsmåder til anvendelse | |
DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
DK3305310T3 (da) | Onkolytisk virusformulering og fremgangsmåde til fremstilling deraf | |
DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
DK3562946T3 (da) | Oncolytiske virusser og terapeutiske molekyler | |
DK3130669T3 (da) | Ny bakteriophag og sammensætning omfattende denne |